Today, a Director at Insmed (NASDAQ: INSM), Steinar Engelsen, bought shares of INSM for $254K.
This recent transaction increases Steinar Engelsen’s holding in the company by 6.06% to a total of $4.46 million. This is Engelsen’s first transaction since reporting a Buy transaction on SLNO back in May 2016
See today’s analyst top recommended stocks >>
Currently, Insmed has an average volume of 950.2K.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $43.40, reflecting a 165.8% upside. Starting in August 2018, INSM received 11 Buy ratings in a row. Five different firms, including Morgan Stanley and Stifel Nicolaus, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.
